While on the subject of RP it concerns me that Faculty, their students, and professional and technical staff have not given due consideration to potential research complications of the use of BNP (Bacitracin, Neomycin, and Polymixin) Cream for the treatment of RP. BNP cream does seem to eliminate opportunistic infection (and by extension the inflammation caused) of exposed rectal mucosa when the lesion is either a redden anus or slightly inflamed (less than 1mm protrusion) but it seems to have little benefit on RP greater than 1mm. We do not use anti-inflammatories such as NSAIDs. Faculty, their students and professional and technical staff need to consider the benefit of using mice with RP especially if they have had extensive treatment with BNP as no medication is benign, i.e. without systemic consequences. While the literature is limited on the research consequences of the three antibiotics in BNP cream it is known the polypeptide antibiotics (Bacitracin and Polymixin) and aminoglycoside antibiotics do have systemic effects.

Further reading:

Hancock, R. E., & Chapple, D. S. (1999). Peptide antibiotics. Antimicrobial Agents and Chemotherapy, 43(6), 1317–23. Retrieved from

Hilchie, A. L., Wuerth, K., & Hancock, R. E. W. (2013). Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nature Chemical Biology, 9(12), 761–768.

Kwiatkowska, B., Maslinska, M., Przygodzka, M., Dmowska-Chalaba, J., Dabrowska, J., & Sikorska-Siudek, K. (2013). Immune system as a new therapeutic target for antibiotics. Advances in Bioscience and Biotechnology, 4(4), 91–101.

Morris, T. H. (1995). Antibiotic therapeutics in laboratory animals. Laboratory Animals, 29(1), 16–36.

Schroeder, R. (2000). Modulation of RNA function by aminoglycoside antibiotics. The EMBO Journal, 19(1), 1–9.